Disclosed is a method of producing Tc-99m by using nuclear resonance fluorescence. More specifically, and a method of preparing Tc-99m by using nuclear resonance fluorescence includes irradiating a ground-state Tc-99 nucleus with a photon beam, thereby causing a nuclear transmutation to proceed such that the nucleus excited to high energy and then undergoes a transition to Tc-99m.

The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.

The present invention relates to stable pharmaceutical compositions of sulfur colloid, which advantageously provide a high radiochemical purity to .sup.99mTc-pertechnetate without causing the gel formation. The compositions include pre-lyophilized and lyophilized compositions of sulfur colloid. It also relates to a non-radioactive kit which upon reconstitution with .sup.99mTc-pertechnetate solution gives stabilized .sup.99mmTc-Sulfur colloid radiopharmaceutical composition. Further, the process for preparation of said compositions and their use for diagnostic purposes are also disclosed.

A process for producing a metal-molybdate material is provided. The process includes a step of reacting a metal molybdenum (Mo) material in a liquid medium with a first acid to provide a Mo composition and combining the Mo composition with a metal source to provide a metal-Mo composition. The metal-Mo composition can be pH adjusted with a base to precipitate a plurality of metal-Mo particulates.

The invention relates to senescent cell biomarkers and the uses thereof. The invention also extends to methods and kits for detecting senescence, and drug conjugates and pharmaceutical compositions for killing senescent cells.

The invention relates to senescent cell biomarkers and the uses thereof. The invention also extends to methods and kits for detecting senescence, and drug conjugates and pharmaceutical compositions for killing senescent cells.

The object of the present invention is to provide a method for incorporating an arbitrary protein, lipid, carbohydrate, or nucleic acid into an exosome. The object can be solved by a method for preparing an exosome, comprising the steps of: (a) adding a biological toxin having a perforating activity to a medium containing cells and incubating the mixture, (b) adding ATP and incubating the mixture, and (c) adding a medium containing calcium ion and incubating the mixture.

Polarized nuclear imaging and spectroscopy systems and methods are disclosed. In some embodiments, nuclei of a radioactive substance are polarized such that the spins of the nuclei are oriented in a specific direction, to generate a polarized radioactive tracer with anisotropic gamma ray emission. The radioactive substance is selected such that the degree of anisotropy is enhanced. A tracer is introduced into a living subject for delivery to a target area of interest in the subject. The tracer is delivered such that nuclear spin relaxation of the tracer is inhibited during transport of the tracer to the target area of interest. Gamma rays from the gamma ray emission are detected, and based on the detected gamma rays and properties associated with the anisotropic gamma ray emission, imaging data and/or spectroscopic data are obtained that are associated with the tracer in the subject. In some embodiments, a radioactive substance is delivered to a target area of interest in the subject and the nuclei of the radioactive substance are polarized following delivery of the radioactive substance to the target area of interest, such that the spins of the nuclei are oriented in a specific direction, to generate a polarized radioactive tracer with anisotropic gamma ray emission. Gamma rays are detected from the gamma ray emission, and based on the detected gamma rays and properties associated with the anisotropic gamma ray emission, imaging data and/or spectroscopic data are obtained that are associated with the tracer in the subject.

Polarized nuclear imaging and spectroscopy systems and methods are disclosed. In some embodiments, nuclei of a radioactive substance are polarized such that the spins of the nuclei are oriented in a specific direction, to generate a polarized radioactive tracer with anisotropic gamma ray emission. The radioactive substance is selected such that the degree of anisotropy is enhanced. A tracer is introduced into a living subject for delivery to a target area of interest in the subject. The tracer is delivered such that nuclear spin relaxation of the tracer is inhibited during transport of the tracer to the target area of interest. Gamma rays from the gamma ray emission are detected, and based on the detected gamma rays and properties associated with the anisotropic gamma ray emission, imaging data and/or spectroscopic data are obtained that are associated with the tracer in the subject. In some embodiments, a radioactive substance is delivered to a target area of interest in the subject and the nuclei of the radioactive substance are polarized following delivery of the radioactive substance to the target area of interest, such that the spins of the nuclei are oriented in a specific direction, to generate a polarized radioactive tracer with anisotropic gamma ray emission. Gamma rays are detected from the gamma ray emission, and based on the detected gamma rays and properties associated with the anisotropic gamma ray emission, imaging data and/or spectroscopic data are obtained that are associated with the tracer in the subject.

A theragnostic method is here described for treating a subject affected by a neoplasia by administering in both the diagnostic and therapeutic steps the same radioisotope, which is a .sup.64Cu.sup.++ salt. Such method comprises a diagnostic step to select a subject, in which there is .sup.64Cu.sup.++ cellular uptake. In case there is no uptake, the treatment is not advisable. In case there is copper uptake from cancer lesions, this has a predictive value of response to treatment. If the subject is selected for the treatment, the method further comprises a step of treating cancer in said subject by administering a therapeutically effective amount of the same .sup.64Cu.sup.++ salt.